Myrtelle Announces Presentation of Positive 12-month Post Treatment Data in its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy at the 2023 Cell & Gene Meeting on the Mesa held by the Alliance for Regenerative Medicine
Wakefield, Mass., October 10, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
This article is featured on another website.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance … Read more
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance … Read more